Regeneron Pharmaceuticals (REGN)

$722.80 -0.87 (-0.12%)
Market Cap 77.98B
Revenue (ttm) 14.20B
Net Income (ttm) 4.41B
EPS (ttm) N/A
PE Ratio 20.45
Forward PE 21.48
Profit Margin 31.07%
Debt to Equity Ratio 0.06
Volume 987,043
Avg Vol 1,112,938
Day's Range N/A - N/A
Shares Out 105.10M
Stochastic %K 5%
Beta 0.37
Analysts Strong Sell
Price Target $769.61

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
Iightning
Iightning Dec. 4 at 7:36 PM
1ightning® Premium Options Alert (Actionable) Ticker: $REGN Contract: Dec 19 $730C Entry: 15.55 Exit: 24.21 Return: +55.68% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 7:01 PM
Canaccord Genuity has updated their rating for Regeneron Pharmaceuticals ( $REGN ) to Buy with a price target of 1057.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 6:46 PM
Enter: $REGN Calls Strike Price: $730 Expiry Date: DEC 26 2025 Buy in Price: $18.20 - $37.60 Sell Price: $56.02 Profit : +49% (Turn every $1 into $1.49) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 5:16 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $725.35 TP1: $724.65 | TP2: $723.95 | TP3: $723.25 Stop Loss: $725.95 EMA9: 725.61 | EMA21: 725.66 RSI14: 45.85 | VWAP: 728.08 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 4:09 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $726.33 TP1: $725.63 | TP2: $724.93 | TP3: $724.23 Stop Loss: $726.93 EMA9: 727.09 | EMA21: 727.82 RSI14: 32.97 | VWAP: 728.24 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 3:42 PM
$REGN AtomicAlerts® Scalp Alert Direction: LONG Entry: $728.93 TP1: $729.63 | TP2: $730.33 | TP3: $731.03 Stop Loss: $728.33 EMA9: 728.96 | EMA21: 728.74 RSI14: 62.16 | VWAP: 728.23 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 2:33 PM
$REGN AtomicAlerts® Scalp Alert Direction: LONG Entry: $732.24 TP1: $732.94 | TP2: $733.64 | TP3: $734.34 Stop Loss: $731.64 EMA9: 727.87 | EMA21: 725.05 RSI14: 79.7 | VWAP: 728.36 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 2:05 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $723.29 TP1: $722.59 | TP2: $721.89 | TP3: $721.19 Stop Loss: $723.89 EMA9: 723.06 | EMA21: 722.44 RSI14: 60.46 | VWAP: 732.95 Paid Alerts: https://atomicalerts.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 2:02 PM
BMO Capital has adjusted their stance on Regeneron Pharmaceuticals ( $REGN ), setting the rating to Outperform with a target price of 725 → 850.
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 12:58 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $723.29 TP1: $722.59 | TP2: $721.89 | TP3: $721.19 Stop Loss: $723.89 EMA9: 723.06 | EMA21: 722.44 RSI14: 60.46 | VWAP: 732.95 Paid Alerts: https://atomicalerts.com
0 · Reply
Latest News on REGN
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 2:13 PM EST - 1 day ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 4:53 PM EST - 1 day ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Dec 1, 2025, 7:00 AM EST - 3 days ago

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?

Nov 30, 2025, 11:15 PM EST - 3 days ago

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Nov 25, 2025, 1:00 AM EST - 9 days ago

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Nov 25, 2025, 1:00 AM EST - 9 days ago

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

SNY

1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month

Nov 24, 2025, 7:58 AM EST - 10 days ago

1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

Nov 21, 2025, 11:05 AM EST - 13 days ago

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

LLY

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Nov 20, 2025, 11:52 AM EST - 14 days ago

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Nov 19, 2025, 4:10 PM EST - 15 days ago

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Nov 19, 2025, 7:00 AM EST - 15 days ago

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 17, 2025, 1:07 PM EST - 17 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 11:57 AM EST - 17 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Nov 13, 2025, 7:00 AM EST - 21 days ago

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know

Nov 13, 2025, 5:15 AM EST - 21 days ago

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know

LLY

Final Trade: LMAT, REGN, BA, TJX

Nov 12, 2025, 6:20 PM EST - 21 days ago

Final Trade: LMAT, REGN, BA, TJX

TJX BA LMAT

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript

Nov 10, 2025, 2:31 PM EST - 24 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Nov 7, 2025, 8:00 AM EST - 27 days ago

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

SNY

Regeneron Announces Investor Conference Presentations

Nov 3, 2025, 4:05 PM EST - 4 weeks ago

Regeneron Announces Investor Conference Presentations

2 Beaten-Down Stocks That Could Be About to Rally

Nov 3, 2025, 7:58 AM EST - 4 weeks ago

2 Beaten-Down Stocks That Could Be About to Rally

NVO

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Oct 31, 2025, 7:00 AM EDT - 4 weeks ago

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Oct 29, 2025, 1:00 PM EDT - 5 weeks ago

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Market Starting To Embrace The 'New' Regeneron

Oct 29, 2025, 12:01 PM EDT - 5 weeks ago

Market Starting To Embrace The 'New' Regeneron

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 1:31 PM EDT - 5 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Oct 28, 2025, 9:13 AM EDT - 5 weeks ago

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron beats quarterly estimates on strong demand for Dupixent

Oct 28, 2025, 7:30 AM EDT - 5 weeks ago

Regeneron beats quarterly estimates on strong demand for Dupixent

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Oct 28, 2025, 6:30 AM EDT - 5 weeks ago

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Has Regeneron Stock Quietly Become A Value Buy?

Oct 27, 2025, 8:35 AM EDT - 5 weeks ago

Has Regeneron Stock Quietly Become A Value Buy?

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

Oct 24, 2025, 4:30 AM EDT - 5 weeks ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IQV IVZ JNJ

7 Stocks Taking The Next Step To Be On Offense

Oct 23, 2025, 7:30 PM EDT - 5 weeks ago

7 Stocks Taking The Next Step To Be On Offense

ACI BIO CNX FCF FDX FIS IAC

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Oct 17, 2025, 7:30 AM EDT - 6 weeks ago

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

Oct 15, 2025, 7:00 AM EDT - 7 weeks ago

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

2 Stocks Down 17% and 21% to Buy Right Now

Oct 14, 2025, 10:00 AM EDT - 7 weeks ago

2 Stocks Down 17% and 21% to Buy Right Now

DXCM

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Oct 12, 2025, 10:18 AM EDT - 7 weeks ago

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?

Oct 10, 2025, 8:35 AM EDT - 7 weeks ago

What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?

US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer

Oct 8, 2025, 4:31 PM EDT - 2 months ago

US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Oct 8, 2025, 2:31 PM EDT - 2 months ago

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

11 Cheap Stocks for a Market That's Too Expensive

Oct 7, 2025, 11:49 AM EDT - 2 months ago

11 Cheap Stocks for a Market That's Too Expensive

DAL FDX UAL

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 2 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Regeneron: Growth Catalysts Incoming

Sep 30, 2025, 4:25 PM EDT - 2 months ago

Regeneron: Growth Catalysts Incoming

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

Sep 30, 2025, 4:05 PM EDT - 2 months ago

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin

Sep 30, 2025, 1:37 PM EDT - 2 months ago

Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin

APH LMT NVDA

2 Beaten-Down Stocks to Buy and Hold for a Decade

Sep 30, 2025, 7:30 AM EDT - 2 months ago

2 Beaten-Down Stocks to Buy and Hold for a Decade

MRNA

Regeneron: Strong R&D Pipeline Drives Growth Outlook

Sep 27, 2025, 9:00 AM EDT - 2 months ago

Regeneron: Strong R&D Pipeline Drives Growth Outlook

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Sep 26, 2025, 7:00 AM EDT - 2 months ago

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Sep 24, 2025, 1:37 PM EDT - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises

Sep 23, 2025, 6:29 PM EDT - 2 months ago

Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Sep 22, 2025, 12:30 AM EDT - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

SNY

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Sep 22, 2025, 12:29 AM EDT - 2 months ago

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study

Sep 19, 2025, 1:23 PM EDT - 2 months ago

Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study

Iightning
Iightning Dec. 4 at 7:36 PM
1ightning® Premium Options Alert (Actionable) Ticker: $REGN Contract: Dec 19 $730C Entry: 15.55 Exit: 24.21 Return: +55.68% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 7:01 PM
Canaccord Genuity has updated their rating for Regeneron Pharmaceuticals ( $REGN ) to Buy with a price target of 1057.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 6:46 PM
Enter: $REGN Calls Strike Price: $730 Expiry Date: DEC 26 2025 Buy in Price: $18.20 - $37.60 Sell Price: $56.02 Profit : +49% (Turn every $1 into $1.49) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 5:16 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $725.35 TP1: $724.65 | TP2: $723.95 | TP3: $723.25 Stop Loss: $725.95 EMA9: 725.61 | EMA21: 725.66 RSI14: 45.85 | VWAP: 728.08 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 4:09 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $726.33 TP1: $725.63 | TP2: $724.93 | TP3: $724.23 Stop Loss: $726.93 EMA9: 727.09 | EMA21: 727.82 RSI14: 32.97 | VWAP: 728.24 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 3:42 PM
$REGN AtomicAlerts® Scalp Alert Direction: LONG Entry: $728.93 TP1: $729.63 | TP2: $730.33 | TP3: $731.03 Stop Loss: $728.33 EMA9: 728.96 | EMA21: 728.74 RSI14: 62.16 | VWAP: 728.23 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 2:33 PM
$REGN AtomicAlerts® Scalp Alert Direction: LONG Entry: $732.24 TP1: $732.94 | TP2: $733.64 | TP3: $734.34 Stop Loss: $731.64 EMA9: 727.87 | EMA21: 725.05 RSI14: 79.7 | VWAP: 728.36 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 2:05 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $723.29 TP1: $722.59 | TP2: $721.89 | TP3: $721.19 Stop Loss: $723.89 EMA9: 723.06 | EMA21: 722.44 RSI14: 60.46 | VWAP: 732.95 Paid Alerts: https://atomicalerts.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 2:02 PM
BMO Capital has adjusted their stance on Regeneron Pharmaceuticals ( $REGN ), setting the rating to Outperform with a target price of 725 → 850.
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 12:58 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $723.29 TP1: $722.59 | TP2: $721.89 | TP3: $721.19 Stop Loss: $723.89 EMA9: 723.06 | EMA21: 722.44 RSI14: 60.46 | VWAP: 732.95 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 12:31 PM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $723.29 TP1: $722.59 | TP2: $721.89 | TP3: $721.19 Stop Loss: $723.89 EMA9: 723.06 | EMA21: 722.44 RSI14: 60.46 | VWAP: 732.95 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 11:25 AM
$REGN AtomicAlerts® Scalp Alert Direction: SHORT Entry: $723.29 TP1: $722.59 | TP2: $721.89 | TP3: $721.19 Stop Loss: $723.89 EMA9: 723.06 | EMA21: 722.44 RSI14: 60.46 | VWAP: 732.95 Paid Alerts: https://atomicalerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 7:28 AM
Hedge Alert Live - Protect Your Portfolio Contract: $REGN $720.00 Put · DEC 12, 2025 Exp Entry Price: $10.10 - $13.80 Exit Price Target: $19.19 Profit Margin: +90% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Iightning
Iightning Dec. 4 at 3:20 AM
1ightning® Premium Options Alert (Actionable) Ticker: $REGN Contract: Dec 19 $725C Entry: 15.50 Exit: 23.64 Return: +52.50% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
ProKnifeCatcher87
ProKnifeCatcher87 Dec. 3 at 8:49 PM
$REGN $800 dec Calls 😋😉 ms crooks will be crooks
0 · Reply
Swimmingincash
Swimmingincash Dec. 3 at 8:30 PM
$REGN REDRUM
0 · Reply
Iwannagofast1
Iwannagofast1 Dec. 3 at 7:57 PM
$REGN even on a down day I’m never mad at her!!! She’s a powerhouse we all know
0 · Reply
kenbkb
kenbkb Dec. 3 at 5:54 PM
$REGN Please (begging is not a solid investment tactic) don't go back to the 600's.
1 · Reply
amunka
amunka Dec. 3 at 4:50 PM
$MCK $REGN oof, hope everyone is ok.
1 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 3:30 PM
Morgan Stanley has adjusted their stance on Regeneron Pharmaceuticals ( $REGN ), setting the rating to Equal-Weight with a target price of 767.
0 · Reply
notreload_ai
notreload_ai Dec. 3 at 1:17 PM
Morgan Stanley upgrades $VRTX on promising kidney pipeline progress and downgrades $REGN due to balanced risk/reward and valuation concerns. https://notreload.xyz/morgan-stanley-updates-vertex-and-regeneron-ratings/
2 · Reply
Quantumup
Quantumup Dec. 3 at 1:13 PM
H.C. Wainwright⬆️ $ARWR's PT to $85 from $80 and reiterated at a Buy rating. $IONS $REGN $ALNY $NVS Here's what H.C. Wainwright had to say in its note to investors: https://x.com/Quantumup1/status/1996204804981313869?s=20
0 · Reply